Journal

Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Wednesday, March 27, 2024
Research, Neurodegenerative disease, Notifiable disease, LDL, Obesity, University, Comparison, PCSK9, Central Florida, Translational research, COVID-19, PD, CSF, Diabetes, Amprion, Patient, CNS, Mayo Clinic, Vaccine, Journal, Biomarker, Travel, Myostatin, Hope, SARS-CoV-2, D&O, Investment, Solid lipid nanoparticle, MDS, Marketing, Parkinson's disease, Hypercholesterolemia

CAPE CANAVERAL, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • CAPE CANAVERAL, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.
  • We also seek to advance UB-311, our anti-Aβ Alzheimer’s candidate, as we resume dialogue with regulatory authorities and partners.
  • General and administrative expenses were $3.4 million and $7.7 million for the three months ended December 31, 2023, and 2022, respectively.
  • General and administrative expenses were $22.4 million and $28.4 million for the years ended December 31, 2023, and 2022, respectively.

Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity

Retrieved on: 
Wednesday, March 27, 2024
Research, Malignancy, Absorption, PD, CSF, Imatinib, Central nervous system, International, Patient, Gastrointestinal tract, Journal, CML, NDA, Pharmacist, Traffic barrier, Cerebrospinal fluid, Insurance, D&O, Dark Ages, Therapy, Division, Blood, Bone marrow, FDA, SAD, Physician, Approximation error, Pharmaceutical industry

The Meeting Minutes confirmed that the 505(b)(2) pathway appears to be appropriate for approval of IkT-001Pro.

Key Points: 
  • The Meeting Minutes confirmed that the 505(b)(2) pathway appears to be appropriate for approval of IkT-001Pro.
  • Inhibikase will host a conference call and webcast to discuss its full-year 2023 financial results and business highlights tomorrow, March 28, 2024, at 8:00am ET.
  • The conference call can be accessed by dialing 1-877-407-0789 (United States) or 1-201-689-8562 (International) and referencing Inhibikase Therapeutics.
  • After the live webcast, the event will be archived on Inhibikase’s website for approximately 90 days after the call.

HeartFlow Initiates DECIDE Registry to Evaluate Utility of HeartFlow AI-Enabled Plaque Analysis for Patients with Suspected Coronary Artery Disease

Retrieved on: 
Tuesday, March 26, 2024
Nuclear, Education, Coronary artery disease, Disease, Safety, Partnership, Physiology, Anatomy, Patient, Journal, Biomarker, AI, Death, Plaque, Society, CAD, CCTA, Charleston Area Medical Center, MACE, Cone Health, Collection, FDA, Physician, IVUS, Hospital

The registry will collect multi-site, real-world information on how the Plaque Analysis product provides enhanced patient insights, empowering physicians and helping to inform their medical management decisions for patients with suspected coronary artery disease (CAD).

Key Points: 
  • The registry will collect multi-site, real-world information on how the Plaque Analysis product provides enhanced patient insights, empowering physicians and helping to inform their medical management decisions for patients with suspected coronary artery disease (CAD).
  • The DECODE study showed that clinicians using the HeartFlow Plaque Analysis changed their management decisions for 66% of patients compared to CCTA alone across various patient presentations and disease stages.
  • “We believe real-world prospective data from the new DECIDE Registry will empower clinicians with enhanced patient insights leveraging HeartFlow Plaque Analysis to improve patient outcomes.
  • The primary endpoint for this registry will highlight change in medical management after HeartFlow Plaque Analysis compared to after CCTA alone.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cassava, NYCB, Amylyx, and InMode and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, March 26, 2024
Apoptosis, Patient, AMX0035, Science, New York Community Bank, NYCB, P.C, Initiative, ACL, Scientific misconduct, IBD, Confidentiality, Safety, Injury, Data management, Food, Signature, Cassava Sciences, ALS, Alzheimer's disease, Defendant, Food and Drug Administration, Journal, Amyotrophy, News, Prescription, Amylyx Pharmaceuticals, Dentist, FDA, City University, Biomarker, Dermatology, Complaint, Investor's Business Daily, Neurobiology of Aging, Cognition, Assumption, Category, BBC World Service, Evercore, Cassava, Pharmaceutical industry

The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.

Key Points: 
  • The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.
  • However, in response, Cassava denied the allegations in the Citizen Petition and instead touted the effectiveness of simufilam and the efficacy of the Company's research programs.
  • On this news, Cassava's stock price fell $2.68 per share, or 15.28%, to close at $14.86 per share on October 13, 2023.
  • For more information on the InMode class action go to: https://bespc.com/cases/INMD

New Study Finds AI-Driven Prediction Models Accurately Predict Critical Care Patient Deterioration and Significantly Reduce False Alarms for Clinicians

Retrieved on: 
Tuesday, April 9, 2024
Software, Telemedicine, Virtual Medicine, Health, FDA, Artificial Intelligence, Medical Devices, Health Technology, Technology, Hospital, UMass Memorial Health, Data science, Caregiver, Risk, CLEW, Journal, Mortality, Intensive care unit, Telehealth, MD, Respiratory failure, Critical care, WakeMed, Nursing care plan, Fatigue, ICU

The prediction models used in the study are a part of CLEW’s intelligent clinical surveillance platform.

Key Points: 
  • The prediction models used in the study are a part of CLEW’s intelligent clinical surveillance platform.
  • It also supports the health system with capacity management, by providing early identification of potential bottlenecks caused by unexpected deterioration.
  • In addition to demonstrating its superior accuracy, the study concluded that the CLEW system generated 50-times fewer alarms than other leading systems.
  • In busy and overburdened critical care environments, this can greatly reduce alarm fatigue and the associated cognitive burden on caregivers.

Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)

Retrieved on: 
Monday, April 8, 2024
Research, FDA, Genetics, Clinical Trials, Cardiology, Biotechnology, Health, Pharmaceutical, Science, JAMA, American Medical Association, Cardiovascular disease, Serum, Patient, Journal, RNA, MD, Therapy, Moyamoya disease, Safety, Small RNA, APOLLO, ASCVD, Pharmaceutical industry

“Positive phase 1 data published in JAMA demonstrate treatment with zerlasiran produced sustained reductions in Lp(a) concentrations with a well-tolerated profile using varying dosing regimens,” said Curtis Rambaran, MD, Chief Medical Officer at Silence and senior author of the publication.

Key Points: 
  • “Positive phase 1 data published in JAMA demonstrate treatment with zerlasiran produced sustained reductions in Lp(a) concentrations with a well-tolerated profile using varying dosing regimens,” said Curtis Rambaran, MD, Chief Medical Officer at Silence and senior author of the publication.
  • Results from the single ascending dose portion of the trial in healthy participants were previously published in the April 2022 issue of JAMA, linked here .
  • Secondary outcomes included the serum levels of zerlasiran and effects on Lp(a) serum concentrations.
  • Zerlasiran is currently being evaluated in the ALPACAR-360 phase 2 study in subjects with baseline Lp(a) levels at or over 125 nmol/L at high risk of ASCVD events.

Applied Physics Launches Warp Drive Simulator

Retrieved on: 
Tuesday, April 9, 2024
Aerospace, Technology, Manufacturing, Security, Other Science, Other Technology, Satellite, Research, Software, Internet, Science, APL, Physics, Classical, Applied physics, Warp, Professional corporation, Journal, Quantum gravity, Multimedia, Weaving

Today, Applied Physics®, a multidisciplinary group of international scientists and engineers, announced the groundbreaking launch of Warp Factory— a toolkit designed for the theoretical testing and advancement of realistic warp drive technologies.

Key Points: 
  • Today, Applied Physics®, a multidisciplinary group of international scientists and engineers, announced the groundbreaking launch of Warp Factory— a toolkit designed for the theoretical testing and advancement of realistic warp drive technologies.
  • View the full release here: https://www.businesswire.com/news/home/20240408213718/en/
    Physicists can generate and refine an array of warp drive designs with Warp Factory by Applied Physics.
  • Science fiction is now inching closer to science fact.”
    The field of warp drives has experienced a resurgence since 2021 when a series of papers, including Applied Physics’ “ Introducing Physical Warp Drives ,” suggested that warp drives could be constructed in accordance with the laws of physics.
  • Operating within the fabric of Applied Physics, the Advanced Propulsion Laboratory (APL) represents the cutting edge of warp drive research.

Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients

Retrieved on: 
Monday, April 8, 2024
Research, Surgery, Genetics, Clinical Trials, Cardiology, Biotechnology, Health, General Health, Science, Biopsy, Reward, Plasma, International Society, Cohort (statistics), Physician, Risk, AUC, Nucleic acid thermodynamics, Patient, Journal, DNA, Lung transplantation, Heart transplantation, MD, NIH, NTRA, Hospital, Molecule, Bangladesh Technical Education Board, Medicare, Oportunidades, Annual general meeting, NPV

“We are encouraged by the results of these two prospective studies,” said Sangeeta Bhorade, MD, chief medical officer of organ health at Natera.

Key Points: 
  • “We are encouraged by the results of these two prospective studies,” said Sangeeta Bhorade, MD, chief medical officer of organ health at Natera.
  • That study showed the Prospera Heart test had an overall area under the curve (AUC) of 0.86 for identifying acute rejection in over 800 samples from 200 adults with heart transplants.
  • The DTRT-2 (DNA-Based Transplant Rejection Test) study, published recently in Pediatric Transplantation , was sponsored by the National Institutes of Health (NIH).
  • A total of 487 samples from 160 heart transplant recipients were evaluated, of which 78 were pediatric and 82 were adult patients.

Study of NFL Alumni Cohort Finds Majority Suffer From Heart Disease Without Knowing It

Retrieved on: 
Sunday, April 7, 2024
Health, Sports, Football, Other Health, Other Science, Research, Science, Blood pressure, TTE, FACC, African Americans, Prevalence, Aortic stenosis, National Football League, Patient, Education, Ageing, Journal, History, MD, City, Male, American College, TAVR, EKG, AFL, Interventional cardiology, Alumni association, NFL, National Football League Alumni, Hypertension, Pharmaceutical industry

Edwards Lifesciences (NYSE: EW) announced the release of data from the HUDDLE study that examined the prevalence of heart disease and associated risk factors among members of the National Football League (NFL) Alumni Association and their families.

Key Points: 
  • Edwards Lifesciences (NYSE: EW) announced the release of data from the HUDDLE study that examined the prevalence of heart disease and associated risk factors among members of the National Football League (NFL) Alumni Association and their families.
  • Results of the HUDDLE study indicated that the prevalence of hypertension in the 498 screened participants was 83.8%, though only about half (46.5%) self-reported a history of hypertension.
  • Conducted across eight U.S. cities in cooperation with NFL Alumni Health, a subsidiary of the NFL Alumni Association, HUDDLE was a cross sectional study of NFL alumni and their family members aged 50 years and above.
  • Study participants self-reported their medical histories and participated in heart health education and screenings that included blood pressure, electrocardiogram (EKG) and echocardiogram.

FORTY-THREE PHYSICIANS FROM UNITED DIGESTIVE PARTNER PRACTICES NAMED CASTLE CONNOLLY TOP DOCTORS 2024

Retrieved on: 
Tuesday, April 9, 2024
Education, Journal, Faculty, Castle Connolly Medical, Gastroenterology, Medical research, Digestive, Physician, Health, Nursing

ATLANTA, April 9, 2024 /PRNewswire/ -- Forty-three physicians from six partner practices of United Digestive have been honored by Castle Connolly as Top Doctors for 2024 for their demonstrated excellence in clinical care, among many other factors.

Key Points: 
  • ATLANTA, April 9, 2024 /PRNewswire/ -- Forty-three physicians from six partner practices of United Digestive have been honored by Castle Connolly as Top Doctors for 2024 for their demonstrated excellence in clinical care, among many other factors.
  • Recipients of the Top Doctors distinction represent the top seven percent of all practicing physicians in the United States.
  • "We are incredibly proud of our 43 physicians who have been recognized as Castle Connolly Top Doctors for 2024," said Dr. Neal C. Patel, CEO of United Digestive.
  • For more information about United Digestive, its partner practices, and Top Doctors recipients, please visit www.uniteddigestive.com .